Published in Cell Growth Differ on May 01, 1992
A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol (1994) 2.11
Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc Natl Acad Sci U S A (1995) 1.43
Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol (2002) 1.24
Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol (2002) 1.18
Lymphoma models for B cell activation and tolerance. X. Anti-mu-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc. J Exp Med (1994) 1.10
Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol (2000) 1.04
Cyclin D3 sensitizes tumor cells to tumor necrosis factor-induced, c-Myc-dependent apoptosis. Mol Cell Biol (1996) 0.92
Modulation of the IL-1 cytokine network in keratinocytes by intracellular IL-1 alpha and IL-1 receptor antagonist. Clin Exp Immunol (1995) 0.86
Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J Cancer Res Clin Oncol (2009) 0.85
Defects in transforming growth factor-beta signaling cooperate with a Ras oncogene to cause rapid aneuploidy and malignant transformation of mouse keratinocytes. Proc Natl Acad Sci U S A (1999) 0.83
Okadaic acid regulation of the retinoblastoma gene product is correlated with the inhibition of growth factor-induced cell proliferation in mouse fibroblasts. Proc Natl Acad Sci U S A (1993) 0.82
Dysregulation of autocrine TGF-beta isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts. Br J Cancer (1996) 0.82
Effects of transforming growth factor beta-1 on growth-regulatory genes in tumour-derived human oral keratinocytes. Br J Cancer (1995) 0.82
Synergistic role of c-Myc and ERK1/2 in the mitogenic response to TGF beta-1 in cultured rat nucleus pulposus cells. Arthritis Res Ther (2008) 0.80
Cutaneous HPV8 and MmuPV1 E6 Proteins Target the NOTCH and TGF-β Tumor Suppressors to Inhibit Differentiation and Sustain Keratinocyte Proliferation. PLoS Pathog (2017) 0.75
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol (1989) 8.68
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84
Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science (1984) 5.20
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med (1987) 4.35
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34
TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell (1990) 4.28
BRCA1 is secreted and exhibits properties of a granin. Nat Genet (1996) 4.26
Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature (1987) 4.19
Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A (1982) 3.88
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol (1990) 3.81
Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc Natl Acad Sci U S A (1986) 3.71
TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell (1990) 3.55
Growth factors and cancer. Cancer Res (1986) 3.48
Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol (1991) 3.38
Transforming growth factor production by chemically transformed cells. Cancer Res (1981) 3.36
Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A (1986) 3.04
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem (2001) 3.04
Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med (1998) 3.03
Specific binding to cultured cells of 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci U S A (1984) 3.01
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet (1995) 2.91
Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res (1986) 2.83
The cell biology of transforming growth factor beta. Biochim Biophys Acta (1990) 2.81
Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest (1987) 2.74
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol (1997) 2.72
Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (1989) 2.63
Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell (1990) 2.63
Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem (1999) 2.56
In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2. Development (1990) 2.53
Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst (1998) 2.21
Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol (1988) 2.20
Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res (1988) 2.20
Transforming growth factors and the regulation of cell proliferation. Eur J Biochem (1990) 2.15
Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev (1993) 2.13
Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci U S A (1989) 2.09
Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol (1990) 2.09
Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07
Ultrastructural studies of vasopressin effect on isolated perfused renal collecting tubules of the rabbit. J Cell Biol (1968) 2.06
Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways. Science (1988) 2.05
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A (1988) 2.03
Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci U S A (1990) 2.01
Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol Endocrinol (1989) 2.00
Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res (1986) 1.97
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. Mol Cell Biol (1991) 1.93
p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol (1999) 1.90
Polyadenylylated RNA complementary to a mouse retrovirus-like multigene family is rapidly and specifically induced by epidermal growth factor stimulation of quiescent cells. Proc Natl Acad Sci U S A (1982) 1.89
Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest (1987) 1.88
Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol (2001) 1.87
Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol (1988) 1.86
Transforming growth factor beta and cell cycle regulation. Cancer Res (1995) 1.84
Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res (1999) 1.81
Integrated control of growth and differentiation of normal human prokeratinocytes cultured in serum-free medium: clonal analyses, growth kinetics, and cell cycle studies. J Cell Physiol (1984) 1.81
Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol (2001) 1.79
Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier's disease: supportive evidence form humans and transgenic mice. Gastroenterology (1992) 1.77
Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. J Clin Invest (1986) 1.77
Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol Cell Biol (1989) 1.76
Production of transforming growth factors by human colon cancer lines. Cancer Res (1986) 1.74
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem (1999) 1.71
Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol (1987) 1.68
Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol (1997) 1.68
Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67
Comparison of intra- and extracellular transforming growth factors from nontransformed and chemically transformed mouse embryo cells. Cancer Res (1983) 1.66
Transforming growth factor type beta regulation of actin mRNA. J Cell Physiol (1986) 1.62
Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res (1987) 1.61
Differential expression of genes encoding TGFs beta 1, beta 2, and beta 3 during murine palate formation. Dev Biol (1990) 1.59
A homozygous nonsense mutation in the beta 3 chain gene of laminin 5 (LAMB3) in Herlitz junctional epidermolysis bullosa. Genomics (1994) 1.59
Lead ion and phosphatase histochemistry. I. Nonenzymatic hydrolysis of nucleoside phosphates by lead ion. J Histochem Cytochem (1966) 1.59
Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor-beta 1. Cancer Res (1987) 1.59
Pitfalls in the use of lead ion for histochemical localization of nucleoside phosphatases. J Histochem Cytochem (1968) 1.58
WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. Am J Med Genet (2000) 1.58
Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-beta receptor. J Biol Chem (1995) 1.57
Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem (1998) 1.55
Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc (1992) 1.53
Ophthalmic abnormalities in patients with cutaneous T-cell lymphoma. Ophthalmology (1999) 1.53
Effect of cell proliferation on levels and diversity of poly(A)-containing mRNA. Cell (1976) 1.53
Gene expression in chemically transformed mouse embryo cells: selective enhancement of the expression of C type RNA tumor virus genes. Cell (1977) 1.52
Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol (1993) 1.52
Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. J Biol Chem (1989) 1.51
Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol (1993) 1.50
Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J Virol (1991) 1.50
Differential effects of epidermal growth factor, transforming growth factor, and insulin on DNA and protein synthesis and morphology in serum-free cultures of AKR-2B cells. Cancer Res (1984) 1.48
Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ (1998) 1.48
Cell density and culture factors regulate keratinocyte commitment to differentiation and expression of suprabasal K1/K10 keratins. J Invest Dermatol (1995) 1.48
Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells. Proc Natl Acad Sci U S A (1988) 1.47
Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell (1999) 1.46
Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol (2010) 1.46
STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol (2000) 1.45
p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene (2007) 1.45